Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response

Y. Mytsyk, S. Pasichnyk, I. Dutka, I. Dats, D. Vorobets, M. Skrzypczyk, Y. Uteuliyev, A. Botikova, K. Gazdikova, P. Kubatka, P. Urdzik, P. Kruzliak

. 2020 ; 20 (2) : 277-287. [pub] 20200205

Language English Country Italy

Document type Clinical Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc21012633

Grant support
VEGA 1/0873/18 Agentúra na Podporu Výskumu a Vývoja

Accurate prediction of early treatment response to systemic therapy (ST) with tyrosine kinase inhibitors (TKI) in patients with metastatic renal cell carcinoma (mRCC) could help avoid ineffective and expensive treatment with serious side effects. Neither RECIST v.1.1 nor Choi criteria successfully discriminate between patients with mRCC who received ST having a short or long time to progression (TTP). There is no biomarker, which is able to predict early therapeutic response to TKIs application in patients with mRCC. The goal of our study was to investigate the potential of apparent diffusion coefficient (ADC) of diffusion-weighted imaging (DWI) of MRI in prediction of early therapeutic response to ST with pazopanib in patients with mRCC. The retrospective study enrolled 32 adult patients with conventional mRCC who received pazopanib (mean duration-7.5 ± 3.45). The mean duration of follow-up was 11.85 ± 4.34 months. In all patients as baseline examination and 1 month after treatment, 1.5T MRI including DWI sequence was performed followed by ADC measurement of the main renal lesion. For assessment of the therapeutic response, RECIST 1.1 is used. Partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 12 (37.50%), 10 (31.25%) and 10 (31.25%) cases with mean TTP of 10.33 ± 2.06 months (95% confidence interval, CI = 9.05-11.61), 7.40 ± 2.50 months (95% CI = 5.61-9.19) and 4.20 ± 1.99 months (95% CI = 2.78-5.62) accordingly (p < 0.05). There was no difference in change of main lesions' longest size 1 month after ST in patients with PR, SD and PD. Comparison of mean ADC values before and 1 month after systemic treatment showed significant decrease by 19.11 ± 10.64% (95% CI = 12.35-25.87) and by 7.66 ± 6.72% (95% CI = 2.86-12.47) in subgroups with PR and SD, respectively (p < 0.05). There was shorter TTP in patients with mRCC if ADC of the main renal lesion 1 month after the ST increased from the baseline less than 1.73% compared to patients with ADC levels above this threshold: 5.29 ± 3.45 versus 9.50 ± 2.04 months accordingly (p < 0.001). Overall, our findings highlighted the use of ADC as a predictive biomarker for early therapeutic response assessment. Use of ADC will be effective and useful for reliable prediction of responders and non-responders to systemic treatment with pazopanib.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012633
003      
CZ-PrNML
005      
20210507101932.0
007      
ta
008      
210420s2020 it f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10238-020-00612-9 $2 doi
035    __
$a (PubMed)32026157
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Mytsyk, Yulian $u Department of Urology, Lviv National Medical University n.a. Danylo Halytsky, Pekarska Str. 69, Lviv, Ukraine
245    10
$a Systemic treatment of the metastatic renal cell carcinoma: usefulness of the apparent diffusion coefficient of diffusion-weighted MRI in prediction of early therapeutic response / $c Y. Mytsyk, S. Pasichnyk, I. Dutka, I. Dats, D. Vorobets, M. Skrzypczyk, Y. Uteuliyev, A. Botikova, K. Gazdikova, P. Kubatka, P. Urdzik, P. Kruzliak
520    9_
$a Accurate prediction of early treatment response to systemic therapy (ST) with tyrosine kinase inhibitors (TKI) in patients with metastatic renal cell carcinoma (mRCC) could help avoid ineffective and expensive treatment with serious side effects. Neither RECIST v.1.1 nor Choi criteria successfully discriminate between patients with mRCC who received ST having a short or long time to progression (TTP). There is no biomarker, which is able to predict early therapeutic response to TKIs application in patients with mRCC. The goal of our study was to investigate the potential of apparent diffusion coefficient (ADC) of diffusion-weighted imaging (DWI) of MRI in prediction of early therapeutic response to ST with pazopanib in patients with mRCC. The retrospective study enrolled 32 adult patients with conventional mRCC who received pazopanib (mean duration-7.5 ± 3.45). The mean duration of follow-up was 11.85 ± 4.34 months. In all patients as baseline examination and 1 month after treatment, 1.5T MRI including DWI sequence was performed followed by ADC measurement of the main renal lesion. For assessment of the therapeutic response, RECIST 1.1 is used. Partial response (PR), stable disease (SD) and progressive disease (PD) were observed in 12 (37.50%), 10 (31.25%) and 10 (31.25%) cases with mean TTP of 10.33 ± 2.06 months (95% confidence interval, CI = 9.05-11.61), 7.40 ± 2.50 months (95% CI = 5.61-9.19) and 4.20 ± 1.99 months (95% CI = 2.78-5.62) accordingly (p < 0.05). There was no difference in change of main lesions' longest size 1 month after ST in patients with PR, SD and PD. Comparison of mean ADC values before and 1 month after systemic treatment showed significant decrease by 19.11 ± 10.64% (95% CI = 12.35-25.87) and by 7.66 ± 6.72% (95% CI = 2.86-12.47) in subgroups with PR and SD, respectively (p < 0.05). There was shorter TTP in patients with mRCC if ADC of the main renal lesion 1 month after the ST increased from the baseline less than 1.73% compared to patients with ADC levels above this threshold: 5.29 ± 3.45 versus 9.50 ± 2.04 months accordingly (p < 0.001). Overall, our findings highlighted the use of ADC as a predictive biomarker for early therapeutic response assessment. Use of ADC will be effective and useful for reliable prediction of responders and non-responders to systemic treatment with pazopanib.
650    _2
$a senioři $7 D000368
650    _2
$a inhibitory angiogeneze $x terapeutické užití $7 D020533
650    _2
$a karcinom z renálních buněk $x diagnostické zobrazování $x farmakoterapie $x mortalita $x patologie $7 D002292
650    _2
$a difuzní magnetická rezonance $x metody $7 D038524
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a ledviny $x diagnostické zobrazování $7 D007668
650    _2
$a nádory ledvin $x diagnostické zobrazování $x farmakoterapie $x mortalita $x patologie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyrimidiny $x terapeutické užití $7 D011743
650    _2
$a ROC křivka $7 D012372
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sulfonamidy $x terapeutické užití $7 D013449
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pasichnyk, Serhiy $u Department of Urology, Lviv National Medical University n.a. Danylo Halytsky, Pekarska Str. 69, Lviv, Ukraine
700    1_
$a Dutka, Ihor $u Medical center "Euroclinic", Lviv, Ukraine
700    1_
$a Dats, Ihor $u Department of Radiology, Lviv National Medical University n.a. Danylo Halytsky, Lviv, Ukraine
700    1_
$a Vorobets, Dmytro $u Department of Urology, Lviv National Medical University n.a. Danylo Halytsky, Pekarska Str. 69, Lviv, Ukraine
700    1_
$a Skrzypczyk, Michał $u Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland
700    1_
$a Uteuliyev, Yerzhan $u Department of Postgraduate Education and Research, Kazakhstan Medical University, Almaty, Kazakhstan
700    1_
$a Botikova, Andrea $u Faculty of Health and Social Work, Trnava University, Trnava, Slovakia
700    1_
$a Gazdikova, Katarina $u Department of General Medicine, Faculty of Medicine, Slovak Medical University, Limbova 12, 8303, Bratislava, Slovakia
700    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine in Martin, Comenius University, Martin, Slovakia
700    1_
$a Urdzik, Peter $u Department of Gynaecology and Obstetrics, Faculty of Medicine, Pavol Jozef Safarik University and Louis Pasteur University Hospital, Tr. SNP 1, 04001, Kosice, Slovakia
700    1_
$a Kruzliak, Peter $u Department of Internal Medicine, Brothers of Mercy Hospital, Polni 553/3, 63900, Brno, Czech Republic. kruzliakpeter@gmail.com
773    0_
$w MED00006222 $t Clinical and experimental medicine $x 1591-9528 $g Roč. 20, č. 2 (2020), s. 277-287
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32026157 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101931 $b ABA008
999    __
$a ok $b bmc $g 1650905 $s 1133012
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 20 $c 2 $d 277-287 $e 20200205 $i 1591-9528 $m Clinical and Experimental Medicine $n Clin Exp Med $x MED00006222
GRA    __
$a VEGA 1/0873/18 $p Agentúra na Podporu Výskumu a Vývoja
LZP    __
$a Pubmed-20210420

Find record

Citation metrics

Archiving options